TP53 and pancreatic neoplasm: In one of the most successful attempts to date to target mutant p53 using CRISPR, Sayed, et al. [103] used the recently introduced adenine base system to target a pancreatic cancer cell line (PANC-1) expressing the TP53 mutation, R273H.